Hikma Closes Acquisition of US Sterile Injectables Provider Custopharm.

MANews-(C)2009-2022

UK-based pharmaceutical company Hikma Pharmaceuticals plc (OTC: HKMPY) has closed the acquisition of US-based generic sterile injectables firm Custopharm Inc. from Water Street Healthcare Partners, the company said.

Hikma paid an initial cash consideration of USD 375m on a debt and cash-free basis, with a further USD 50m in contingent consideration payable upon the achievement of certain commercial milestones.

Custopharm, a US-based generic sterile injectables company with a differentiated product portfolio and R and D pipeline, currently markets its products in the US through its commercial arm Leucadia Pharmaceuticals.

The deal was announced on...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT